



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

May 12, 2022

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code- 532523</b>	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol- Biocon</b>
---	--

**Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').**

Dear Sir/Madam

In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended March 31, 2022, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

*Mayank*



**Mayank Verma**  
Company Secretary and Compliance Officer

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
									Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary														
1	Blocon Limited		Kiran Mazumdar-Shaw		Executive Chairperson	Remuneration	Not applicable	12.4										
2	Blocon Limited		Siddharth Mittal		Managing Director & CEO	Remuneration	Not applicable	17.3										
3	Blocon Limited		Indranil Sen		Chief Financial Officer	Remuneration	Not applicable	4.9										
4	Blocon Limited		Mayank Verma		Company Secretary	Remuneration	Not applicable	2.1										
5	Blocon Limited		Daniel M Bradbury		Independent Director	Sitting fees and commission	Not applicable	3.6										
6	Blocon Limited		Mary Harney		Independent Director	Sitting fees and commission	Not applicable	2.8										
7	Blocon Limited		Vijay K Kuchroo		Independent Director	Sitting fees and commission	Not applicable	2.4										
8	Blocon Limited		M Damodaran		Independent Director	Sitting fees and commission	Not applicable	3.0										
9	Blocon Limited		Bobby K Parikh		Independent Director	Sitting fees and commission	Not applicable	3.7										
10	Blocon Limited		Ravi Mazumdar		Non-Executive Director	Sitting fees and commission	Not applicable	2.7										
11	Blocon Limited		Eric Mazumdar		Non-Executive Director	Sitting fees and commission	Not applicable	2.5										
12	Syngene International Limited		Vijay K Kuchroo		Independent Director	Sitting fees and commission	Not applicable	3.2										
13	Syngene International Limited		Kiran Mazumdar-Shaw		Non- Executive Chairperson	Sitting fees and commission	Not applicable	3.8										
14	Blocon Biologics Limited		Kiran Mazumdar-Shaw		Executive Chairperson	Remuneration	Not applicable	12.6										
15	Blocon Biologics Limited		Daniel M Bradbury		Independent Director	Sitting fees and commission	Not applicable	3.6										
16	Blocon Biologics Limited		Bobby K Parikh		Independent Director	Sitting fees and commission	Not applicable	3.6										
17	Blocon Biologics UK Limited		Daniel M Bradbury		Independent Director	Sitting fees and commission	Not applicable	3.0										
18	Blocon Biologics UK Limited		John Shaw		Director	Sitting fees and commission	Not applicable	3.0										
19	Blocon Biologics UK Limited		Ravi Mazumdar		Director	Sitting fees and commission	Not applicable	3.0										
20	Syngene International Limited		Catherine Rosenberg		Relative of Director	Sitting fees and commission	Not applicable	3.5										
21	Bicara Therapeutics Inc.		Claire Mazumdar		Chief Executive Officer	Remuneration	Not applicable	20.5										
22	Blocon FZ LLC		Neo Blocon FZ LLC		Joint Venture of Holding Company	Purchase of goods	Not applicable	199.4										
23	Blocon FZ LLC		Neo Blocon FZ LLC		Joint Venture of Holding Company	Sales promotion expenses	Not applicable	14.1										
24	Blocon FZ LLC		Neo Blocon FZ LLC		Joint Venture of Holding Company	Rent expense	Not applicable	0.2										
25	Blocon FZ LLC		Neo Blocon FZ LLC		Joint Venture of Holding Company	Trade and other payables	Not applicable		363.4	474.3								
26	Blocon Limited		Neo Blocon FZ LLC		Joint Venture	Expenses incurred on behalf of the related party	Not applicable	1.0	0.4									
27	Blocon Limited		Neo Blocon FZ LLC		Joint Venture	Other receivables	Not applicable			0.0	0.2							
28	Syngene International Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Sale of services	Not applicable	144.0										
29	Biofusion Therapeutics Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Sale of services	Not applicable	279.5										
30	Blocon Biologics Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Sale of services	Not applicable	0.9										
31	Blocon Pharma Inc.		Bicara Therapeutics Inc.		Associate of Holding Company	Interest income	Not applicable	12.6										
32	Blocon Pharma Inc.		Bicara Therapeutics Inc.		Associate of Holding Company	Loan given	Not applicable	683.2		683.2			Loan	4%	Repayable on demand	Unsecured	Business purpose	
33	Blocon Limited		Bicara Therapeutics Inc.		Associate company	Trade and other receivables	Not applicable		299.3	449.0								
34	Syngene International Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Trade and other receivables	Not applicable		335.4	354.5								
35	Biofusion Therapeutics Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Trade and other receivables	Not applicable		-	401.8								
36	Blocon Biologics Limited		Bicara Therapeutics Inc.		Associate of Holding Company	Trade and other receivables	Not applicable		-	12.0								
37	Blocon Pharma Inc.		Bicara Therapeutics Inc.		Associate of Holding Company	Other receivables	Not applicable		25.3	38.0								
38	Blocon Biologics Limited		Narayana Hrudayalaya Limited		Enterprise in which a director of the Company is a member of board of directors	Sale of goods and services	Not applicable	39.0										
39	Syngene International Limited		Narayana Hrudayalaya Limited		Enterprise in which a director of the Company is a member of board of directors	Sale of goods and services	Not applicable	0.7										
40	Syngene International Limited		Narayana Hrudayalaya Limited		Enterprise in which a director of the Company is a member of board of directors	Health services availed	Not applicable	2.8										
41	Blocon Biologics Limited		Narayana Hrudayalaya Limited		Enterprise in which a director of the Company is a member of board of directors	Trade and other receivables	Not applicable		18.0	21.0								
42	Blocon Limited		Blocon Foundation		Trust in which key management personnel are the Board of Trustees	CSR expenditures	Not applicable	40	19.3									
43	Syngene International Limited		Blocon Foundation		Trust in which key management personnel are the Board of Trustees	CSR expenditures	Not applicable	24.5										
44	Blocon Biologics Limited		Blocon Foundation		Trust in which key management personnel are the Board of Trustees	CSR expenditures	Not applicable	21.0										
45	Blocon Limited		Jeeves		Enterprise in which relative to a director of the Company is proprietor	Other expenses	Not applicable	25	9.7									
46	Syngene International Limited		Jeeves		Enterprise in which relative to a director of the Company is proprietor	Other expenses	Not applicable	1.6										
47	Blocon Biologics Limited		Jeeves		Enterprise in which relative to a director of the Company is proprietor	Other expenses	Not applicable	16.0										
48	Syngene International Limited		Immuneel Therapeutics Private Limited		Enterprise in which a director of the Company is a member of board of directors	Sale of services	Not applicable	1.1										

Notes:  
 1. Share-based compensation expense allocable to key management personnel is Rs 33 which is not included in the remuneration disclosed above.  
 2. The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.  
 3. The above does not include allowance for expected credit loss amounting to Rs. 278 towards receivable from associate company

